Corium Reports Fiscal Year-End 2014 Financial Results and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Corium Reports Fiscal Year-End 2014 Financial Results and Recent Corporate Developments

MENLO PARK, Calif., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the fiscal year ended September 30, 2014 and reported on recent corporate developments.

Recent Corporate Developments

  • Corium entered into an agreement on November 14, 2014 with Capital Royalty Group (CRG LP) that will result in $10 million of additional debt financing and will extend the maturity of all debt to CRG LP from June 2017 to June 2019. The closing of this transaction is expected to occur on or before December 15, 2014. Coupled with the $48.5 million in net proceeds from Corium's initial public offering (IPO) in April 2014, the company has significantly increased its ability to advance its programs toward multiple clinical milestones through 2017.

  • Corium achieved promising preclinical pharmacokinetic results from the company's lead Alzheimer's disease program, showing in vivo transdermal delivery rates predictive of therapeutic blood levels in humans. Sustained, constant and reproducible blood levels were demonstrated with a once-weekly transdermal system for up to seven days. These results support commencement of the planned Phase 1 clinical study in the first half of 2015.
     
  • Under a contract awarded by the World Health Organization, Corium has initiated a new transdermal vaccine research program focusing on the evaluation of the company's MicroCor® technology in the development of a new needle-free polio vaccine. Corium's MicroCor technology provides ease of administration and room temperature stability, features that can facilitate broader utilization of the polio vaccine in remote areas of the developing world.
     
  • In September 2014, Corium announced the appointment of Paul Goddard, Ph.D. to the Company's Board of Directors. Dr. Goddard brings more than 30 years of experience in the life science industry, having held senior executive positions in several leading pharmaceutical and biotechnology companies.
     
  • In October 2014, Corium was the recipient of Procter & Gamble's annual James N. Gamble Award for Product Innovation, in recognition of Corium's leadership in applying advanced transdermal delivery systems to the Premium Crest Whitestrips line of products, including the new Crest 3D products, which have achieved unmatched market success as the preferred solution for teeth whitening. 

"2014 has been a transformational year for Corium, during which we created a solid foundation for growth in our business and continuing product innovation. We strengthened our financial position with an IPO in April, and now Capital Royalty has reaffirmed its support of our continued growth strategy," said Peter D. Staple, Corium's President and Chief Executive Officer. "We have executed on our plan to accelerate development of several new product candidates, and have already achieved promising results in our proprietary programs, as well as key milestones in our partnered and co-development programs. Corium is well-positioned to build on this success in 2015, as we advance toward key clinical and commercial milestones that we expect will deliver significant shareholder value."  

Financial Results

Corium reported total revenues for the fiscal year ended September 30, 2014 (FY2014) of $42.4 million. This amount reflected a decline from revenues of $50.3 million for FY2013,  primarily due to the anticipated declines in full-year product revenues from both Clonidine TDS (marketed by Teva Pharmaceuticals) and Fentanyl TDS (marketed by Par Pharmaceutical), as well as reductions in contract research and development revenues from programs that have reached the final stages of process development, partially offset by an increase in contract research and development revenues from new co-development programs as well as from new partner-funded programs.

In September 2014, Corium recognized $1.8 million in non-cash product revenue that had been previously deferred since 2007. The recognition of this revenue related to the expiration of a contractual liability, and will not have an impact on future revenues.

Total research and development (R&D) expenses for FY 2014 were $22.8 million, compared with $17.4 million for FY2013. The increase primarily reflects the addition of new partner-funded development programs, two co-development programs in which all development costs are shared equally with the partner, and Corium's increased investment in its proprietary programs.

General and administrative (G&A) expenses for FY2014 were $9.1 million, compared with $6.5 million for FY2013. The increase was primarily attributable to increased costs associated with becoming a public company, stock-based compensation expense and the timing of incentive compensation.

Corium reported a net loss for FY2014 of $9.9 million, or ($0.99) per share on a fully-diluted basis, compared with a net loss of $13.9 million, or ($6.24) per share, for FY2013. The loss per share in FY2013 was impacted by the use of the significantly smaller number of average shares outstanding prior to the IPO, and does not reflect the earnings or losses per share that will occur with Corium's post-IPO capital structure.  As a result of Corium's IPO on April 2, 2014, the fair value of the subordinated note embedded derivative liability that had a value of $7.4 million at the end of FY2013 was determined to be zero upon the debt's conversion into equity at the closing of the IPO, resulting in a non-cash, non-recurring gain of $7.4 million for FY2014. Without the effect of the $7.4 million non-cash gain in FY2014 and the $7.4 million non-cash charge in FY2013 recorded upon initial recognition of this item, Corium would have recognized non-GAAP net losses for FY2014 and FY2013 of $17.3 million and $6.5 million, respectively.

Cash and cash equivalents at September 30, 2014 were $36.4 million.

Conference Call and Webcast Details

Corium will host a conference call today at 5 p.m. EST to discuss the financial results for the fiscal year ended September 30, 2014. Investors and analysts can access the call toll-free by dialing 844-831-3024 (United States) or +1 315-625-6887 (international). No passcode is required for this call. The conference call will also be available via a live audio webcast on the Investors section of Corium's website at http://ir.coriumgroup.com/events.cfm. Please access the website 10 minutes prior to the start of the call to ensure adequate time for any software downloads that may be necessary. A replay of the conference call will be available for two weeks and may be accessed by dialing toll-free 855-859-2056 (United States) or +1 404-537-3406 (international) and entering the conference ID# 30831078 or by visiting Corium's website.

Statement regarding use of non-GAAP financial measures

The company reported non-GAAP net loss in this release in addition to, and not as a substitute for, or superior to, net loss and net loss per share calculated in accordance with GAAP.

Management believes the presentation of net loss and net loss per share that excludes the non-cash, non-recurring charge or gain from the change in fair value of an embedded derivative provides useful supplemental information to investors and facilitates the analysis of the company's core operating results and comparison of net loss and net loss per share across reporting periods. Management also believes that this supplemental non-GAAP information is therefore useful to investors in analyzing and assessing the company's past and future operating performance.

The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our business strategy, debt financing,  clinical trial timing and plans, the achievement of clinical and commercial milestones, and the advancement of our technologies and our proprietary and partnered products and product candidates. Forward-looking statements are based on management's current expectations and projections and are subject to risks and uncertainties, which may cause Corium's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect Corium's business and its financial results are detailed in the final prospectus for our initial public offering, dated as of April 2, 2014, and filed with the Securities and Exchange Commission pursuant to Rule 424(b)(4) on April 3, 2014 (File No. 333-194279), Corium's most recent Form 10-Q filed with the Securities and Exchange Commission on August 12, 2014, and other reports as filed from time to time with the Securities and Exchange Commission. Corium undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.

About Corium

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's advanced transdermal and transmucosal delivery systems. Corium has developed, and is the sole commercial manufacturer of, six prescription drug and consumer products with partners Teva Pharmaceuticals, Par Pharmaceutical and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch currently in Phase 3 trials co-developed with Agile Therapeutics and additional transdermal products co-developed with Teva. Corium has multiple proprietary programs in preclinical and clinical development for the treatment of osteoporosis, benign prostatic hyperplasia and neurological disorders. For further information, please visit www.coriumgroup.com.

CORIUM INTERNATIONAL, INC.
Condensed Statements of Operations and Comprehensive Loss
(unaudited, in thousands, except share and per share data)
     
  Years Ended September 30,
  2014 2013
     
Revenues:    
Product revenues $ 32,202 $ 38,704
Contract research and development revenues 9,026 10,750
Other revenues 1,212 816
Total revenues 42,440 50,270
Costs and operating expenses:    
Cost of product revenues 20,204 24,828
Cost of contract research and development revenues 15,391 11,856
Research and development expenses 7,365 5,496
General and administrative expenses 9,095 6,525
Amortization of intangible assets 547 541
Gain on disposal and sale and leaseback of equipment (112) (177)
Total costs and operating expenses 52,490 49,069
Income (Loss) from operations (10,050) 1,201
Interest income 7 9
Interest expense (6,961) (7,705)
Change in fair value of preferred stock warrant liability (274) (14)
Change in fair value of subordinated note embedded derivative liability 7,367 (7,367)
Loss before income taxes (9,911) (13,876)
Income tax expense (1) (1)
Net loss and comprehensive loss $ (9,912) $ (13,877)
Net loss attributable to common stockholders, basic and diluted (9,912) (13,877)
Net loss per share attributable to common stockholders, basic and diluted $ (0.99) $ (6.24)
Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted 10,043,640 2,222,981
 
 
 
CORIUM INTERNATIONAL, INC.
Condensed Balance Sheets
(unaudited, in thousands)
     
  As of September 30,
  2014 2013
     
ASSETS    
Current assets:    
Cash and cash equivalents $ 36,395 $ 13,581
Accounts receivable 4,168 3,129
Unbilled accounts receivable 1,385 1,495
Inventories, net 2,592 4,508
Prepaid expenses and other current assets 1,292 1,038
Total current assets 45,832 23,751
Property and equipment, net 12,658 12,622
Debt financing costs, net 571 902
Intangible assets, net 6,683 6,647
Notes receivable — related parties — 100
TOTAL ASSETS $ 65,744 $ 44,022
LIABILITIES, CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)    
Current liabilities:    
Accounts payable $ 2,512 $ 2,748
Accrued expenses and other current liabilities 4,008 3,374
Bank line of credit — 3,873
Long-term debt, current portion 107 457
Capital lease obligations, current portion 760 1,029
Preferred stock warrant liability — 560
Recall liability, current portion 774 1,004
Deferred contract revenues, current portion 301 2,112
Total current liabilities 8,462 15,157
Long-term interest payable — 11,590
Long-term debt, net of current portion 38,155 36,956
Convertible notes — 9,399
Subordinated note — 13,000
Subordinated note embedded derivative liability — 7,367
Capital lease obligations, net of current portion 891 1,652
Recall liability, net of current portion 2,936 3,828
Deferred contract revenues, net of current portion 3,500 3,688
Total liabilities 53, 944 102,637
Convertible preferred stock — 57,261
Redeemable common stock — 3,224
Stockholders' equity (deficit):    
Common stock 18 2
Additional paid-in capital 114,117 (26,679)
Accumulated deficit (102, 335) (92,423)
Total stockholders' equity (deficit) 11,800 (119,100)
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) $ 65,744 $ 44,022

Robert S. Breuil Chief Financial Officer Investor and Media Contact: Karen L. Bergman BCC Partners (650) 575-1509

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Jumia’s Breakeven Retreat Invites Legal Scrutiny

Updated Category News Views 25

Jumia’s credibility problem did not arrive wearing a disguise. The company spent much of 2026 telling investors that a fourth-quarter Adjusted EBITDA breakeven was still on the table, then discarded that target after reporting third-quarter results. For holders of NYSE:JMIA, that kind of reversal stings because the promise was not some stray talking point; it was...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 81

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
Trinity's Minneapolis Move Signals Freight Momentum

Updated Category News Views 120

A suite change inside downtown Minneapolis is usually wallpaper, but this one carries a little more weight. Trinity Logistics has moved its Minneapolis team from Suite 1850 to Suite 1700 at 100 S. 5th Street, saying the larger space is needed for continued growth and future opportunity. Nobody should confuse an office relocation with a freight-cycle victory lap. Still,...

Continue Reading
Litmus Gets $475 Million as Music Rights Mature Further

Updated Category News Views 107

Music royalties just got another serious pile of institutional money, and Litmus is holding the shovel. The company announced roughly $475 million of new capital commitments from Carlyle and investment funds managed by KKR, a notable vote of confidence in a platform that did not even exist before 2022. This is not some celebrity vanity vehicle buying a famous chorus and...

Continue Reading
Mining's Biodiversity Map Sharpens Location Risks

Updated Category News Views 106

Twelve thousand pins on a map do not settle the mining industry's nature problem, but they do make it much harder to pretend the problem is evenly spread. ICMM's new Global Mining and Metals Biodiversity Dataset overlays 12,000 large-scale formal mining, smelting, refining and processing facilities with ecosystem-condition and conservation indicators. For investors...

Continue Reading
U.S. Patriot's Veteran Hiring Earns a Real National Nod

Updated Category News Views 43

A workforce award can be cheap wallpaper, but this one has some heft. U.S. Patriot, the veteran-founded and veteran-led military goods retailer owned by GALLS, landed on Military Times’ 2026 Best for Vets: Employers list, placing third in retail and first in Kentucky. The recognition covers 250 organizations, and this is U.S. Patriot’s fourth consecutive appearance....

Continue Reading
AMP Tests Debt Market With €1.25 Billion Green Notes

Updated Category News Views 167

Refinancing season has arrived early at Ardagh Metal Packaging, and it is carrying a hefty €1.25 billion price tag. AMP has launched senior secured floating-rate green notes, with proceeds intended to retire two batches of secured debt due in 2028 and leave additional cash on the balance sheet for general corporate purposes, including capital expenditure. This is not...

Continue Reading
Esquire Spotlight Puts Trauma Cleanup Work in Focus

Updated Category News Views 52

A national magazine profile is an odd milestone for a business built around other people’s worst days. David Lesaffre, co-owner and operator of T.A.C.T. 48, T.A.C.T. AZ, and T.A.C.T. Fort Worth, has been featured by Esquire in a piece called “The Trauma Cleaners.” The attention is deserved, frankly, because biohazard remediation is one of those necessary services...

Continue Reading
Star Catcher Powers a Public-Interest Space Bet Ahead

Updated Category News Views 56

A satellite’s battery budget is a rotten place for humanitarian priorities to die. Common Space and Star Catcher are trying to remove that bottleneck through a partnership that is easy to like on principle and still deserves a clear-eyed look on execution. Common Space, a nonprofit developing an independent, community-governed high-resolution satellite constellation,...

Continue Reading
Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 101

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Customer Care: Apivia and SoundHound Unite

Updated Category News Views 247

Transforming Customer Service with AI SoundHound AI (NASDAQ: SOUN) has joined forces with Apivia Courtage, a notable entity within France's AEMA Group, which is recognized as a leading mutual insurance organization. This partnership aims to implement agent-based artificial intelligence into Apivia Courtage's customer service systems through the innovative Amelia 7...

Continue Reading
Taiwan's Bold Pedal Into Sustainability: EUROBIKE 2026

Updated Category News Views 40

Stepping Up the Game at EUROBIKE 2026 Ask any veteran cyclist: The road to innovation is a winding one, and Taiwan's Bicycle Industry seems determined to tackle every curve head-on at EUROBIKE 2026. This isn't just about flashy tech; it's a full-blown commitment to smart, low-carbon mobility—a real 'get on the bike or get left behind' moment. Unveiling the AI-Powered...

Continue Reading
TDI Welcomes Jay Truesdale as New Chief Executive Officer

Updated Category News Views 389

TD International Appoints New Leadership TD International LLC (TDI), a prominent strategic advisory and risk intelligence firm, has announced significant leadership changes with the appointment of Jay Truesdale as Chief Executive Officer. This move marks a pivotal moment for TDI, as it looks to leverage Truesdale's considerable expertise in geopolitics and global markets....

Continue Reading
Canaan Inc. Streamlines Focus on Core Cryptocurrency Market

Updated Category News Views 258

Canaan Inc. Streamlines Focus on Core Cryptocurrency Market Canaan Inc. (NASDAQ: CAN) has recently taken a significant step in refining its business operations. The company is discontinuing its non-core AI semiconductor division to concentrate on its core strengths in the ever-evolving world of cryptocurrency. This strategic decision is aimed at enhancing efficiencies and...

Continue Reading
Ascentage Pharma's Impressive Growth in 2025: A Review

Updated Category News Views 567

Overview of Ascentage Pharma's Interim Results Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) recently announced its interim unaudited financial results for the first half of 2025. The report highlights significant growth, particularly in product sales, and provides exciting updates on ongoing clinical programs and commercial strategies. The company's...

Continue Reading